Drug intelligence / Profile preview

AB 1527

Development stage: Unknown
Lead developer: ABVC BioPharma

Overview

**AB 1527** was an ABVC BioPharma and Rgene co-development candidate described as an ovarian cancer combination therapy. The publicly available agreement record does not identify its constituent active substances, molecular modality, biological targets, mechanism of action, formulation, route of administration, clinical phase, or manufacturer. ABVC and Rgene removed the candidate from their co-development and commercialization pipeline through an amendment dated November 10, 2020.

Beyond the preview

Go deeper on AB 1527.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB 1527.

Explore the full profile